Last 48 quarters of trend data · Healthcare · Medical - Devices
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Insulet Corporation's quarterly P/E stands at 40.4x, down 69.3% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has compressed 35.0% YoY to 29.2x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 41.89 | 40.35 | 49.35 | 62.24 | 245.45 | 131.31 | 46.96 | 53.88 | 19.48 | 58.70 | 36.65 | 56.96 | 184.83 |
| — | -69.3% | +5.1% | +15.5% | +1160.1% | +123.7% | +28.1% | -5.4% | -89.5% | -75.0% | -88.0% | — | — | |
| P/S Ratio | 3.78 | 4.83 | 6.41 | 7.72 | 8.55 | 8.55 | 8.09 | 7.91 | 7.62 | 7.15 | 7.43 | 6.78 | 12.75 |
| — | -43.5% | -20.8% | -2.4% | +12.1% | +19.5% | +8.9% | +16.6% | -40.2% | -54.2% | -46.7% | -41.9% | +1.0% | |
| P/B Ratio | 6.92 | 11.31 | 13.26 | 15.76 | 15.17 | 14.63 | 15.96 | 15.40 | 14.92 | 15.98 | 20.69 | 19.33 | 36.51 |
| — | -22.7% | -17.0% | +2.4% | +1.7% | -8.5% | -22.8% | -20.4% | -59.1% | -64.1% | -52.2% | -48.1% | +2.0% | |
| P/FCF | 27.09 | 42.82 | 104.18 | 52.09 | 32.02 | 94.48 | 52.73 | 59.93 | 57.91 | 49.68 | 80.29 | 87.37 | 195.22 |
| — | -54.7% | +97.6% | -13.1% | -44.7% | +90.2% | -34.3% | -31.4% | -70.3% | — | — | -50.0% | -68.0% | |
| EV / EBITDA | 18.01 | 29.22 | 28.86 | 39.53 | 39.43 | 44.97 | 37.86 | 40.47 | 52.83 | 44.07 | 31.86 | 42.80 | 107.04 |
| — | -35.0% | -23.8% | -2.3% | -25.4% | +2.0% | +18.8% | -5.4% | -50.6% | -65.9% | -76.4% | -80.7% | — | |
| EV / EBIT | 22.30 | 29.22 | 34.90 | 39.90 | 117.80 | 86.71 | 41.27 | 46.50 | 62.70 | 50.85 | 34.84 | 49.07 | 137.86 |
| — | -66.3% | -15.4% | -14.2% | +87.9% | +70.5% | +18.5% | -5.2% | -54.5% | -70.2% | -80.2% | -95.9% | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Insulet Corporation's operating margin was 16.0% in Q1 2026, down 2.6 pp QoQ and up 0.4 pp YoY. The trailing four-quarter average of 17.5% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 3.4% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 71.6% | 69.5% | 72.5% | 72.2% | 69.7% | 71.9% | 72.1% | 69.3% | 67.7% | 69.5% | 70.9% | 67.8% | 66.8% |
| — | -3.4% | +0.6% | +4.2% | +2.8% | +3.5% | +1.8% | +2.3% | +1.4% | +3.4% | +20.5% | +22.7% | +5.1% | |
| Operating Margin | 17.5% | 16.0% | 18.7% | 16.7% | 18.7% | 15.6% | 18.3% | 16.2% | 11.2% | 12.9% | 20.9% | 12.7% | 7.8% |
| — | +2.7% | +2.0% | +2.9% | +67.2% | +21.1% | -12.4% | +27.9% | +42.2% | +66.5% | +228.3% | +1388.4% | +188.0% | |
| Net Margin | 9.1% | 12.0% | 13.0% | 12.4% | 3.5% | 6.2% | 16.9% | 14.2% | 38.6% | 11.7% | 20.3% | 12.0% | 6.9% |
| — | +92.2% | -23.1% | -13.0% | -91.0% | -46.6% | -16.8% | +18.8% | +460.7% | +75.4% | +340.7% | +886.1% | +158.9% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 18.1% | 6.5% | 7.0% | 6.2% | 1.6% | 2.8% | 8.6% | 7.3% | 21.1% | 6.8% | 15.4% | 8.9% | 5.2% |
| — | +132.2% | -18.9% | -16.0% | -92.4% | -58.8% | -43.9% | -18.1% | +308.0% | +39.1% | +310.1% | +830.8% | +164.2% | |
| ROA | 7.9% | 2.9% | 3.3% | 2.7% | 0.6% | 1.1% | 3.3% | 2.6% | 6.9% | 2.0% | 4.1% | 2.1% | 1.2% |
| — | +175.2% | -0.8% | +2.7% | -90.6% | -45.8% | -19.4% | +22.7% | +486.6% | +88.5% | +430.9% | +980.1% | +169.8% | |
| ROIC | 20.1% | 6.8% | 6.3% | 5.0% | 5.0% | 3.9% | 5.0% | 4.0% | 2.6% | 2.8% | 5.4% | 2.9% | 1.7% |
| — | +74.9% | +25.7% | +24.1% | +94.4% | +38.0% | -7.1% | +38.7% | +53.2% | +81.0% | +272.3% | +1454.9% | +197.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Insulet Corporation's Debt/EBITDA ratio is 0.2x, down from 5.9x last quarter — comfortably within a safe range. The current ratio has weakened 43.9% YoY to 2.49x, tightening the short-term liquidity position. Debt/Equity has declined for 5 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.69 | 0.01 | 0.69 | 0.75 | 0.97 | 1.27 | 1.17 | 1.25 | 1.40 | 1.77 | 1.98 | 2.34 | 2.52 |
| — | -98.9% | -40.9% | -40.4% | -30.8% | -28.1% | -40.6% | -46.5% | -44.5% | -36.2% | -34.3% | -28.9% | -24.5% | |
| Debt / EBITDA | 1.79 | 0.15 | 5.94 | 7.38 | 9.88 | 15.34 | 10.87 | 12.78 | 18.97 | 18.51 | 11.57 | 19.33 | 28.41 |
| — | -99.0% | -45.4% | -42.2% | -47.9% | -17.1% | -6.1% | -33.9% | -33.2% | -40.5% | -67.9% | -74.2% | — | |
| Current Ratio | 2.78 | 2.49 | 2.78 | 2.87 | 2.23 | 4.43 | 3.54 | 3.64 | 3.56 | 3.70 | 3.47 | 3.22 | 3.31 |
| — | -43.9% | -21.6% | -21.1% | -37.3% | +19.7% | +2.0% | +12.9% | +7.7% | +8.0% | -2.5% | -18.1% | -28.7% | |
| Quick Ratio | 2.11 | 1.81 | 2.11 | 2.18 | 1.79 | 3.59 | 2.73 | 2.76 | 2.68 | 2.71 | 2.58 | 2.31 | 2.34 |
| — | -49.4% | -22.6% | -20.9% | -33.0% | +32.4% | +5.7% | +19.3% | +14.4% | +11.9% | -1.2% | -21.7% | -33.0% | |
| Interest Coverage | 5.94 | 12.46 | 7.46 | 8.87 | 2.45 | 6.23 | 13.79 | 7.74 | 5.65 | 6.13 | 17.09 | 6.16 | 3.94 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Deep dive into PODD consensus models and risk factors.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PODD stock.
Insulet Corporation's current P/E is 41.9x. The average P/E over the last 4 quarters is 99.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Insulet Corporation's current operating margin is 17.5%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Insulet Corporation's business trajectory between earnings reports.